Centessa Pharmaceuticals (NASDAQ:CNTA) Trading Down 5.3% Following Insider Selling

Centessa Pharmaceuticals plc (NASDAQ:CNTA)’s share price fell 5.3% on Monday following insider selling activity. The company traded as low as $17.85 and last traded at $18.02. 142,969 shares traded hands during trading, a decline of 77% from the average session volume of 617,110 shares. The stock had previously closed at $19.03.

Specifically, insider Karen M. Anderson sold 30,526 shares of the stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $19.03, for a total transaction of $580,909.78. Following the completion of the transaction, the insider now directly owns 54,322 shares in the company, valued at approximately $1,033,747.66. This represents a 35.98 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CTO Tia L. Bush sold 11,000 shares of the stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $16.86, for a total transaction of $185,460.00. Following the transaction, the chief technology officer now owns 121,503 shares in the company, valued at $2,048,540.58. This trade represents a 8.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In other news, insider Karen M. Anderson sold 6,471 shares of the business’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $16.86, for a total value of $109,101.06. Following the completion of the sale, the insider now owns 54,322 shares of the company’s stock, valued at approximately $915,868.92. The trade was a 10.64 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Guggenheim reaffirmed a “buy” rating on shares of Centessa Pharmaceuticals in a report on Monday. TD Cowen began coverage on shares of Centessa Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating for the company. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $25.83.

Centessa Pharmaceuticals Price Performance

The stock has a 50-day moving average of $16.78 and a two-hundred day moving average of $15.54. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.05. Research analysts expect that Centessa Pharmaceuticals plc will post -1.6 EPS for the current fiscal year.

Institutional Trading of Centessa Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of CNTA. JPMorgan Chase & Co. grew its position in Centessa Pharmaceuticals by 40.1% during the fourth quarter. JPMorgan Chase & Co. now owns 190,385 shares of the company’s stock valued at $3,189,000 after purchasing an additional 54,482 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of Centessa Pharmaceuticals by 39.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 18,909 shares of the company’s stock valued at $317,000 after buying an additional 5,316 shares during the period. GAMMA Investing LLC grew its holdings in shares of Centessa Pharmaceuticals by 29.1% during the 4th quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock valued at $64,000 after acquiring an additional 865 shares in the last quarter. Lord Abbett & CO. LLC acquired a new position in shares of Centessa Pharmaceuticals in the third quarter worth $4,305,000. Finally, Franklin Resources Inc. raised its holdings in shares of Centessa Pharmaceuticals by 99.1% during the third quarter. Franklin Resources Inc. now owns 2,302,546 shares of the company’s stock worth $38,360,000 after acquiring an additional 1,145,823 shares in the last quarter. Institutional investors and hedge funds own 82.01% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.